Inside The Shift Toward Greener, Faster, Smarter Drug Manufacturing

By Dave Henderson, Ph.D, MBA, Head of R&D Labs, Asymchem Ltd

Drug manufacturing is undergoing a major shift as sustainability targets, energy pressures, and development speed converge to reshape process strategy. Flow chemistry, biocatalysis, automation, and high‑throughput experimentation are emerging as essential tools for reducing waste, improving reaction control, and building more resilient operations.

These technologies allow teams to maintain steady‑state conditions, optimize reactions in real time, and transition more easily from lab innovation to scalable continuous manufacturing. The result is a technical landscape where efficiency and environmental stewardship are no longer competing priorities but aligned drivers of competitive advantage. Organizations that embrace these approaches are accelerating timelines, strengthening process robustness, and expanding their ability to handle challenging chemistries.

The full article explores how these advancements are redefining expectations for development partners and shaping the next generation of manufacturing infrastructure.